A pioneering treatment, an antibody termed PRN100, is to be given to a patient with sporadic Creutzfeldt-Jakob disease for the first time.
Browsing: treatment strategies
Some EU healthcare systems have been reported to lack the capacity to rapidly move an Alzheimer’s treatment from approval into widespread clinical use.
The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.
At the FENS Forum of Neuroscience (7–11 July, Berlin, Germany), researchers have come together to present their work on novel treatments for multiple sclerosis.
Alzheimer’s Society has worked with an expert taskforce to develop goals and detailed recommendations for research into dementia prevention, diagnosis, intervention and care by 2025.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
Natural antioxidants in hybrids for the treatment of neurodegenerative diseases: a successful strategy?
This article examines physicochemical and cell-based assays and in vitro studies that have assessed the antioxidant properties of multitarget compounds.
Researchers have uncovered the role of cellular prion protein (PrPC) in Neurofibromatosis Type 2 (NF2) related tumors, offering hope to neuro-tumor patients.
This review explores the current literature on SRS treatment for both metastatic and benign intradural tumors, with a focus on differential use for intramedullary and intradural extramedullary neoplasms.
Could this new approach drive Parkinson’s disease into the age of personalized medicine?